ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Myocardial Infarction"

  • Abstract Number: 0239 • ACR Convergence 2020

    Adjudicated MACE and VTE in the Filgotinib RA Program: Integrated Analysis from Phase 2 and 3 Clinical Trials

    Christina Charles-Schoeman1, Sang-Cheol Bae2, Arvind Chopra3, Stanley Cohen4, Jeffrey R Curtis5, Jacques-Eric Gottenberg6, Edward C Keystone7, Kunihiro Yamaoka8, Peter Nash9, J-Abraham Simon-Campos10, William Stohl11, Michael Weinblatt12, Rene Westhovens13, Jeff Siegel14, Iyabode Tiamiyu14, Lei Ye14, Deyuan Jiang14, Franziska Matzkies14, Angelika Jahreis14, John S. Sundy14 and Jon Giles15, 1University of California, Los Angeles, Los Angeles, CA, 2Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 3Center for Rheumatic Diseases, Pune, India, 4University of Texas Southwestern Medical School at Dallas, and Metroplex Clinical Research Center, Dallas, TX, 5Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 6Strasbourg University Hospital, Strasbourg, France, 7Mount Sinai Hospital, Toronto, ON, Canada, 8Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan, 9School of Medicine Griffith University, Brisbane, Queensland, Australia, 10Köhler & Milstein Research, Mérida, Mexico, 11University of Southern California Keck School of Medicine, Los Angeles, CA, 12Brigham and Women's Hospital, Boston, MA, 13University Hospitals Leuven, Belgium, Leuven, Belgium, 14Gilead Sciences, Inc., Foster City, CA, 15Columbia University, New York, NY

    Background/Purpose: Filgotinib (FIL)—an oral, selective Janus kinase 1 inhibitor (JAKi)—improved RA signs and symptoms in three phase 3 trials. Despite the efficacy of FIL and…
  • Abstract Number: 1181 • ACR Convergence 2020

    Gains in Cardiovascular Risk Knowledge Through Web Based Educational Intervention for Rheumatoid Arthritis Patients

    Meenakshi Jolly1, Courtney O'Brien1, Aman Kugasia2, Anna Gorfin3, Lauren Klebek3, Joshlean Fair3 and Joel Block1, 1Rush University, Chicago, IL, 2Arthritis Clinic of Cypress and Katy, PA, Katy, TX, 3Rush University, Chicago

    Background/Purpose: Cardiovascular disease (CVD) is a leading cause of mortality in rheumatoid arthritis (RA). Ischemic heart disease in RA is often silent and precedes myocardial…
  • Abstract Number: 1390 • ACR Convergence 2020

    Outcomes of Systemic Sclerosis Patients Who Were Primarily Admitted for Acute Myocardial Infarction from 2016 to 2017: Insights from the National Inpatient Sample

    Atefeh Vafa1, Omid Behnamfar2 and Yih Chang Lin3, 1University of South Florida, Tampa, FL, 2University of California San Diego, La Jolla, CA, 3University of South Florida, Morsani College of Medicine, Tampa, FL

    Background/Purpose: Several systemic autoimmune rheumatic diseases have been shown to increase coronary artery disease (CAD) risk, notable rheumatoid arthritis and systemic lupus erythematosus.  However, data…
  • Abstract Number: 1424 • ACR Convergence 2020

    Outcomes of Hospitalizations for Acute Myocardial Infarction in Patients with ANCA Associated Vasculitis from the National Inpatient Sample

    Atefeh Vafa1, Marielys Figueroa Sierra1, Omid Behnamfar2, Hamayon Babary1, Suraiya Afroz1 and Yih Chang Lin3, 1University of South Florida, Tampa, FL, 2University of California San Diego, La Jolla, CA, 3University of South Florida, Morsani College of Medicine, Tampa, FL

    Background/Purpose: Several studies in the past have shown significantly increased risks of cardiovascular disease in patients with ANCA associated vasculitis (AAV). This association is thought…
  • Abstract Number: 1630 • ACR Convergence 2020

    Long-term Safety of Tildrakizumab in Patients with Moderate to Severe Plaque Psoriasis: Incidence of Confirmed Major Adverse Cardiovascular Events Through 3 Years (148 Weeks) from Two Phase 3 Trials

    Lars Iversen1, Christopher EM Griffiths2, Andrea Peserico3, Ignasi Pau-Charles4, Andrew Blauvelt5, Diamant Thaçi6 and Kristian Reich7, 1Aarhus University Hospital, Aarhus, Denmark, 2The University of Manchester, Manchester, United Kingdom, 3DIMED University of Padua, Padua, Italy, 4Almirall R&D, Barcelona, Spain, 5Oregon Medical Research Center, Portland, OR, 6Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, 7Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, and Skinflammation®, Hamburg, Germany

    Background/Purpose: Tildrakizumab (TIL) is a high-affinity anti–interleukin-23p19 monoclonal antibody that is approved for the treatment of moderate to severe plaque psoriasis. The objective of this…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.